AIEQ1.950%
as of Jul 20
WST
GrowthWEST PHARMACEUTICAL SERVICES INC
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
Close · 3M
+42.03%
Held by 2 AI ETFs
QRFT0.060%
as of Jul 8
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals3
Win rate33% (1/3)
Avg buy return+4.14%
AIEQ · Weight decrease · 2d
A series of small, consecutive daily reductions in AIEQ's allocation to WST, following an extended period of a stable 2.00% weight, indicates a systematic de-risking by the EquBot-managed fund. This gradual trimming, rather than an abrupt change, suggests that IBM Watson's NLP-driven analysis, feeding into AIEQ’s daily rebalancing and risk overlay, identified a subtle shift in WST's relative appeal. With WST currently priced at $353.71, closely approaching 97% of its 52-week high of $365.74, and reflecting a PER of 46.06 and PBR of 6.23, AIEQ’s hybrid fundamental and sentiment model appears to be prudently adjusting exposure to a company that has seen 61.6% returns over the past year, despite its 11.23% revenue growth and 17.87% ROE.
weight 1.940% → 1.910% (-0.030 pp)·stock up 5.7% in the 30 days before
Jul 11·entry $359.70·now $352.32
-2.05%
since Jul 11
AIEQ · Weight increase · 2d
Currently trading at $365.74, WST has reached 100% of its 52-week high, driven by substantial 30-day, 90-day, and 1-year returns of +19.7%, +49.1%, and +69.5% respectively. This strong upward trajectory and new high point likely generated significant positive sentiment signals from news, filings, and social posts, which IBM Watson's NLP system, central to AIEQ’s strategy, would have detected. The daily rebalancing fund, operating as a broad market, fundamentals + sentiment hybrid, then initiated a position from 0.0000% to 1.9700% on July 1st, further increasing it to 2.0000% on July 3rd. This allocation was likely supported by the company’s 11.23% revenue growth and 17.87% ROE, which, even with a PER of 47.0 and PBR of 6.23, contributed to a favorable ranking in EquBot’s daily risk overlay.
weight 0 → 2.000% (new)·stock up 17.2% in the 30 days before
Jul 3·entry $357.64·now $352.32Fresh
-1.49%
since Jul 3
AIEQ · New entry · 1d
The sudden, single-step entry of 1.9700% on July 1st, after consecutive days of zero allocation, exemplifies AIEQ’s high-turnover, daily rebalancing strategy driven by IBM Watson’s NLP capabilities. This swift allocation to WST, a Health Care stock currently at its 52-week high of $365.00, indicates Watson likely detected a confluence of positive real-time sentiment signals across news, filings, and social posts. EquBot’s risk overlay, informed by these insights, likely factored in WST’s strong recent momentum, with a 30-day return of +20.1%, despite its elevated PER of 47.0. The fund’s hybrid approach of blending fundamentals and sentiment would have also acknowledged WST’s 11.23% revenue growth and 17.87% ROE as compelling factors for inclusion.
weight 0 → 1.970% (new)·stock up 15.4% in the 30 days before
Jul 1·entry $365.00·now $352.32Fresh
-3.47%
since Jul 1
AIEQ · Exit · 1d
The AI ETF likely divested from WST due to its high valuation multiples, specifically a PER of 39.65 and PBR of 6.23, which likely became a significant risk factor relative to its growth and profitability. This rapid removal suggests the AI identified an unfavorable risk-reward profile, possibly anticipating a slowdown or correction. A practical takeaway for retail investors is to always consider a stock's valuation in addition to its fundamentals, as even quality companies can be quickly dropped by AI algorithms if they become too expensive relative to their growth prospects.
weight 0.360% → 0 (exited)·stock up 19.0% in the 30 days before
May 3·entry $300.18·now $352.32
+17.37%
since May 3
AIEQ · Weight decrease · 2d
The AI ETF likely initiated this consecutive weight decrease for WST due to its significantly high valuation multiples, with a PER of 38.53 and PBR of 6.23, which may indicate the algorithm perceives the stock as overvalued relative to its growth trajectory or anticipates a future multiple compression. For retail investors, this serves as a crucial signal to re-evaluate WST's valuation and growth prospects, assessing if their own portfolio’s exposure appropriately balances risk given these elevated multiples.
weight 0.370% → 0.350% (-0.020 pp)·stock up 20.5% in the 30 days before
Apr 29·entry $295.36·now $352.32
+19.28%
since Apr 29
QRFT · New entry · 1d
The AI ETF likely initiated a small position in WST due to its strong profitability, evidenced by a high ROE of 17.87%, and consistent revenue growth within the stable Health Care sector, despite elevated valuation multiples. A practical takeaway for retail investors is to recognize that sophisticated algorithms often prioritize high-quality companies with robust earnings and growth potential, even if traditional valuation metrics like PER and PBR suggest a premium price.
weight 0 → 0.050% (new)·stock up 17.8% in the 30 days before
May 4·entry $300.18·now $352.32Chased
+17.37%
since May 4
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jul 12
The AI ETF AIEQ has recently shown interest in West Pharmaceutical Services, making a new entry and increasing its weight before a slight reduction from its peak. This activity contrasts with the value-investing framework's 'Fail' verdict, which is primarily driven by an inability to fully assess the company's financial health and the lack of a margin of safety at its current high valuation.
- Circle of CompetenceThe business of providing specialized drug containment and delivery systems offers stable unit economics, allowing for reasonably predictable ten-year cash flow projections within the circle of competence.
- Economic MoatWest Pharmaceutical Services benefits from high customer switching costs due to regulatory requirements and product integration, along with a strong reputation for quality in a highly regulated industry, creating a durable economic moat.
- ManagementManagement's candor, capital allocation discipline, and skin in the game cannot be assessed with the provided financial summary.
- Financial HealthCritical financial health criteria such as 10-year ROE trend, operating margin stability, debt manageability, and owner earnings consistency cannot be fully evaluated with the limited data provided, preventing a pass.
- Margin of SafetyThe high valuation multiples (PER 46.06, EV/EBITDA 53.89) suggest the current price offers no defensible discount to a conservative estimate of intrinsic value, failing the margin of safety criterion.
West Pharmaceutical Services operates in a niche providing essential healthcare supplies, exhibiting predictable unit economics and a strong economic moat due to high switching costs and regulatory barriers. However, a comprehensive assessment of financial health and management quality is hampered by insufficient data. Crucially, the current market valuation indicates an absence of a margin of safety, leading to an overall 'Fail' within this value-investing framework.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.